SYNGENE Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,036.5 Cr
verified against source
Revenue YoY
2%
reported change
EBITDA
₹303 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene delivered Q4 FY26 revenue of INR 1,037 crore (2% YoY, 13% sequential) with EBITDA margin of 29% versus 34% in Q4 FY25, impacted by Librela destocking and new facility costs. Full-year FY26 revenue grew 3% with 25% EBITDA margin and 20% PAT decline. The company faces near-term headwinds from Librela supply winding down (minimal volumes expected Q1-Q2 FY27) and facility ramp-up costs at Bayview and Unit 3 Bengaluru. The BMS partnership extension through 2035 and acceleration in CDMO pipeline (Unit 3 biologics, Bayview) provide structural support. FY27 guidance of broadly flat revenue with mid-twenties EBITDA margin reflects transition dynamics, with H2-weighted growth and stronger performance expected from FY28 onward. AI and digital investments aim to enhance discovery, development, and manufacturing capabilities across modalities including peptides, ADCs, and oligonucleotides.
Colored figures show movement against the previous available record.
Guidance to track
- FY2027 will be a transition year with flat revenue performance as Librela impact winds down in Q1-Q2, with growth weighted toward H2 FY27 as new contracts ramp up. Management expects Q1 FY27 to have pronounced Librela destocking impact.
- EBITDA margins expected to be maintained in the mid-twenties through disciplined cost management and sharper operational execution, despite new facility costs being fully baked in.
- H2 FY27 expected to be meaningfully stronger than H1 as new contracts ramp up and business momentum improves, with the company expecting to end FY27 on a growth trajectory.
- FY2028 onwards expected to deliver stronger growth as the healthy pipeline of deal flows translates into revenue, supported by investments in CDMO, biologics, and emerging AI-enabled service lines.
Risks flagged
- Librela supply expected to reach near-zero by Q2 FY27 with only minor volumes in the last quarter. Without incremental revenue plans for Librela or its follow-on molecule Lenivia (Syngene has no commercial participation confirmed), the company faces significant revenue gap requiring rapid offset from other business streams.
- Unit 3 Bengaluru and Bayview U.S. facilities have come online with costs fully flowing through P&L, yet utilization remains low. Management acknowledged this as a factor in FY26 profitability decline, with 12-18 month gestation before meaningful revenue contribution begins.
- When asked directly whether the extended partnership would translate to higher revenues, Peter Bains responded it would grow around U.S. inflation only, with expansion driven by new modality areas rather than guaranteed revenue growth. This suggests near-term BMS revenue may not offset Librela headwind significantly.
- Syngene is undergoing leadership transition with new CEO Siddharth (from Biocon Biologics) and new commercial head Abhijit, plus organizational rebalancing reflected in INR 25 crore (net of tax) exceptional termination charges. Execution during this transition period adds execution risk at a critical juncture.
Key quotes
- FY 2027 will be a transition year for Syngene, with important leadership changes already underway to position this company for its next phase of growth, particularly in CDMO, biologics, and emerging AI-enabled service lines.
- With the investments that we've made in the modalities and the capabilities that we're building, and with the maturation of the pipelines that we're developing on the commercial side, we would expect to see those begin to play through and look beyond 2027 for a more sustainable and higher growth trajectory.
- We expect, as Peter alluded a little bit, that the coming quarters, Q1 and Q2, will have almost no Librela. There is some minor Librela volumes towards the end of the year, but that's about it.
Research modules